Gal Shafirstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gal Shafirstein has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- David A. Bellnier
Roswell Park Cancer Institute (USA)
8 shared publications Emily Oakley
Roswell Park Comprehensive Cancer Center (Roswell Park)
5 shared publicationsSandra Sexton
Comparative Oncology Shared Resources Roswell Park Comprehensive Cancer Center Buffalo New York USA
5 shared publicationsAlan Hutson
Department of Biostatistics and Bioinformatics Roswell Park Comprehensive Cancer Center Buffalo New York USA
4 shared publicationsHassan Arshad
Department of Head and Neck Surgery, Roswell Park, Buffalo, NY, USA
4 shared publicationsLeslie Curtin
Roswell Park
4 shared publications
Latest Publications
- 13 May 2025
- Published by Wiley in Photochemistry and Photobiology
- Vol. 101 (5) , 1279-1290
Image‐based treatment planning for TLD1433 mediated intraoperative photodynamic therapy with an optical surface applicator—A translational rodent study
Several clinical studies suggest that following surgical resection, intraoperative photodynamic therapy (intraoperative PDT) has the potential to reduce local recurrence and improve overall survival in patients diagnosed with pleural dissemination of lung cancer. The response to intraoperative PDT depends on the light dose rate (irradiance) and dose (fluence) as well as the intratumoral concentration of the photosensitizer and oxygenation. We seek to advance intraoperative PDT by improving the control of irradiance and fluence with image‐based treatment planning for an optical surface applicator (OSA) with a novel photosensitizer (TLD1433) that has shown safety in recent clinical trials. To that end, we tested the accuracy of Monte Carlo‐based simulations of light delivery from the OSA in vitro and in vivo. We assess the safety and biodistribution after the instillation of TLD1433 in the peritoneal cavity of mice and rats, and define the relationship between the intratumoral irradiance and fluence, and the volume of tumor ablation in the peritoneal cavity of rats. The Monte Carlo simulations agreed with light dosimetry measurements at a 5‐mm prescription depth in vitro. An instillation of TLD1433 in the peritoneal cavity of mice is safe and leads to drug accumulation in the tumor and adjacent organs in the peritoneal cavity of rats. A TLD1433‐mediated intraoperative PDT procedure using an instilled dose of 14 mg/kg and 532‐nm laser light induces tumor cell degradation in the peritoneal cavity of rats. Our results suggest that the Monte Carlo simulation can be used as an image‐based treatment plan for administering a controlled PDT procedure with OSA and TLD1433.
- 13 May 2025
- Published by Wiley in Photochemistry and Photobiology
- Vol. 101 (5) , 1279-1290
Image‐based treatment planning for TLD1433 mediated intraoperative photodynamic therapy with an optical surface applicator—A translational rodent study
Several clinical studies suggest that following surgical resection, intraoperative photodynamic therapy (intraoperative PDT) has the potential to reduce local recurrence and improve overall survival in patients diagnosed with pleural dissemination of lung cancer. The response to intraoperative PDT depends on the light dose rate (irradiance) and dose (fluence) as well as the intratumoral concentration of the photosensitizer and oxygenation. We seek to advance intraoperative PDT by improving the control of irradiance and fluence with image‐based treatment planning for an optical surface applicator (OSA) with a novel photosensitizer (TLD1433) that has shown safety in recent clinical trials. To that end, we tested the accuracy of Monte Carlo‐based simulations of light delivery from the OSA in vitro and in vivo. We assess the safety and biodistribution after the instillation of TLD1433 in the peritoneal cavity of mice and rats, and define the relationship between the intratumoral irradiance and fluence, and the volume of tumor ablation in the peritoneal cavity of rats. The Monte Carlo simulations agreed with light dosimetry measurements at a 5‐mm prescription depth in vitro. An instillation of TLD1433 in the peritoneal cavity of mice is safe and leads to drug accumulation in the tumor and adjacent organs in the peritoneal cavity of rats. A TLD1433‐mediated intraoperative PDT procedure using an instilled dose of 14 mg/kg and 532‐nm laser light induces tumor cell degradation in the peritoneal cavity of rats. Our results suggest that the Monte Carlo simulation can be used as an image‐based treatment plan for administering a controlled PDT procedure with OSA and TLD1433.
- Open Access
- 5 August 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1033
Energy Transfer between AGuIX Nanoparticles and Photofrin under Light or X-ray Excitation for PDT Applications
Photodynamic therapy is an accepted therapy cancer treatment. Its advantages encourage researchers to delve deeper. The use of nanoparticles in PDT has several advantages including the passive targeting of cancer cells. The aim of this article is to evaluate the effectiveness of AGuIX nanoparticles (activation and guiding of irradiation by X-ray) in the presence or absence of a photosensitizer, Photofrin, under illumination of 630 nm or under X-ray irradiation. The goal is to improve local tumor control by combining PDT with low-dose-X-ray-activated NPs in the treatment of locally advanced metastatic lung cancer. The study of the energy transfer, which occurs after excitation of Gd/Tb chelated in AGuIX in the presence of Photofrin, was carried out. We could observe the formation of singlet oxygen after the light or X-ray excitation of Gd and Tb that was not observed for AGuIX or Photofrin alone, proving that it is possible to realize energy transfer between both compounds.
- 5 August 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1033
Open AccessEnergy Transfer between AGuIX Nanoparticles and Photofrin under Light or X-ray Excitation for PDT Applications
Photodynamic therapy is an accepted therapy cancer treatment. Its advantages encourage researchers to delve deeper. The use of nanoparticles in PDT has several advantages including the passive targeting of cancer cells. The aim of this article is to evaluate the effectiveness of AGuIX nanoparticles (activation and guiding of irradiation by X-ray) in the presence or absence of a photosensitizer, Photofrin, under illumination of 630 nm or under X-ray irradiation. The goal is to improve local tumor control by combining PDT with low-dose-X-ray-activated NPs in the treatment of locally advanced metastatic lung cancer. The study of the energy transfer, which occurs after excitation of Gd/Tb chelated in AGuIX in the presence of Photofrin, was carried out. We could observe the formation of singlet oxygen after the light or X-ray excitation of Gd and Tb that was not observed for AGuIX or Photofrin alone, proving that it is possible to realize energy transfer between both compounds.
- Open Access
- 17 June 2024
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 31 (3)
Epidemiology and Survival of Malignant Central Airway Obstruction in Lung Cancer Identified on Cross-Sectional Imaging
Background: The prevalence of malignant central airway obstruction at diagnosis and its 5-year incidence are largely unknown, as are basic epidemiological data pertaining to this serious condition. To address these data limitations, we retrospectively collected data from the cohort of patients diagnosed with lung cancer at our institution in 2015 and followed cohort patients 5 years forward, until 2020. Methods: We reviewed index PET/CT or CT scans at the time of lung cancer diagnosis to identify the presence, subtype, and severity of malignant central airway obstruction as well as progression/development over the next 5 years. Results: The prevalence of malignant central airway obstruction affecting the airway lumen by 25% or greater was 17%, and its 5-year incidence of development was 8.2%. Notable associations from the multivariate analysis included a younger age and a stepwise increase in obstruction with increasing stage of disease. Squamous cell carcinoma and small-cell lung cancer were the 2 histologic subtypes with the strongest association with obstruction. The presence of malignant central airway obstruction either at time of diagnosis or on follow-up imaging was associated with significantly shortened survival (multivariate Cox proportional HR for MCAO=1.702, P<0.001). Conclusion: This study provides the first systematic characterization of fundamental epidemiological data on malignant central airway obstructions at a tertiary cancer center in the United States. This data is important to inform research directions and funding efforts of this serious complication. It also serves as a baseline value against which to compare for future studies.
- 17 June 2024
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 31 (3)
Open AccessEpidemiology and Survival of Malignant Central Airway Obstruction in Lung Cancer Identified on Cross-Sectional Imaging
Background: The prevalence of malignant central airway obstruction at diagnosis and its 5-year incidence are largely unknown, as are basic epidemiological data pertaining to this serious condition. To address these data limitations, we retrospectively collected data from the cohort of patients diagnosed with lung cancer at our institution in 2015 and followed cohort patients 5 years forward, until 2020. Methods: We reviewed index PET/CT or CT scans at the time of lung cancer diagnosis to identify the presence, subtype, and severity of malignant central airway obstruction as well as progression/development over the next 5 years. Results: The prevalence of malignant central airway obstruction affecting the airway lumen by 25% or greater was 17%, and its 5-year incidence of development was 8.2%. Notable associations from the multivariate analysis included a younger age and a stepwise increase in obstruction with increasing stage of disease. Squamous cell carcinoma and small-cell lung cancer were the 2 histologic subtypes with the strongest association with obstruction. The presence of malignant central airway obstruction either at time of diagnosis or on follow-up imaging was associated with significantly shortened survival (multivariate Cox proportional HR for MCAO=1.702, P<0.001). Conclusion: This study provides the first systematic characterization of fundamental epidemiological data on malignant central airway obstructions at a tertiary cancer center in the United States. This data is important to inform research directions and funding efforts of this serious complication. It also serves as a baseline value against which to compare for future studies.
- Open Access
Correlation of Bronchoscopy and CT in Characterizing Malignant Central Airway Obstruction
Background: Malignant Central Airway Obstruction (MCAO) presents a significant challenge in lung cancer management, with notable morbidity and mortality implications. While bronchoscopy is the established diagnostic standard for confirming MCAO and assessing obstruction subtype (intrinsic, extrinsic, mixed) and severity, Computed Tomography (CT) serves as an initial screening tool. However, the extent of agreement between CT and bronchoscopy findings for MCAO remains unclear. Methods: To assess the correlation between bronchoscopy and CT, we conducted a retrospective review of 108 patients at Roswell Park Comprehensive Cancer Center, analyzing CT and bronchoscopy results to document MCAO presence, severity, and subtype. Results: CT correctly identified MCAO in 99% of cases (107/108). Agreement regarding obstruction subtype (80.8%, Cohen’s κ = 0.683, p < 0.001), and severity (65%, Quadratic κ = 0.657, p < 0.001) was moderate. CT tended to equally overestimate (7/19) and underestimate (7/19) the degree of obstruction. CT was also poor in identifying mucosal involvement in mixed MCAO. Conclusions: CT demonstrates reasonable agreement with bronchoscopy in detecting obstruction. Nevertheless, when CT indicates a positive finding for MCAO, it is advisable to conduct bronchoscopy. This is because CT lacks reliability in determining the severity of obstruction and identifying the mucosal component of mixed disease.
Open AccessCorrelation of Bronchoscopy and CT in Characterizing Malignant Central Airway Obstruction
Background: Malignant Central Airway Obstruction (MCAO) presents a significant challenge in lung cancer management, with notable morbidity and mortality implications. While bronchoscopy is the established diagnostic standard for confirming MCAO and assessing obstruction subtype (intrinsic, extrinsic, mixed) and severity, Computed Tomography (CT) serves as an initial screening tool. However, the extent of agreement between CT and bronchoscopy findings for MCAO remains unclear. Methods: To assess the correlation between bronchoscopy and CT, we conducted a retrospective review of 108 patients at Roswell Park Comprehensive Cancer Center, analyzing CT and bronchoscopy results to document MCAO presence, severity, and subtype. Results: CT correctly identified MCAO in 99% of cases (107/108). Agreement regarding obstruction subtype (80.8%, Cohen’s κ = 0.683, p < 0.001), and severity (65%, Quadratic κ = 0.657, p < 0.001) was moderate. CT tended to equally overestimate (7/19) and underestimate (7/19) the degree of obstruction. CT was also poor in identifying mucosal involvement in mixed MCAO. Conclusions: CT demonstrates reasonable agreement with bronchoscopy in detecting obstruction. Nevertheless, when CT indicates a positive finding for MCAO, it is advisable to conduct bronchoscopy. This is because CT lacks reliability in determining the severity of obstruction and identifying the mucosal component of mixed disease.
- Open Access
Computational Optimization of Irradiance and Fluence for Interstitial Photodynamic Therapy Treatment of Patients with Malignant Central Airway Obstruction
There are no effective treatments for patients with extrinsic malignant central airway obstruction (MCAO). In a recent clinical study, we demonstrated that interstitial photodynamic therapy (I-PDT) is a safe and potentially effective treatment for patients with extrinsic MCAO. In previous preclinical studies, we reported that a minimum light irradiance and fluence should be maintained within a significant volume of the target tumor to obtain an effective PDT response. In this paper, we present a computational approach to personalized treatment planning of light delivery in I-PDT that simultaneously optimizes the delivered irradiance and fluence using finite element method (FEM) solvers of either Comsol Multiphysics® or Dosie™ for light propagation. The FEM simulations were validated with light dosimetry measurements in a solid phantom with tissue-like optical properties. The agreement between the treatment plans generated by two FEMs was tested using typical imaging data from four patients with extrinsic MCAO treated with I-PDT. The concordance correlation coefficient (CCC) and its 95% confidence interval (95% CI) were used to test the agreement between the simulation results and measurements, and between the two FEMs treatment plans. Dosie with CCC = 0.994 (95% CI, 0.953–0.996) and Comsol with CCC = 0.999 (95% CI, 0.985–0.999) showed excellent agreement with light measurements in the phantom. The CCC analysis showed very good agreement between Comsol and Dosie treatment plans for irradiance (95% CI, CCC: 0.996–0.999) and fluence (95% CI, CCC: 0.916–0.987) in using patients’ data. In previous preclinical work, we demonstrated that effective I-PDT is associated with a computed light dose of ≥45 J/cm2 when the irradiance is ≥8.6 mW/cm2 (i.e., the effective rate-based light dose). In this paper, we show how to use Comsol and Dosie packages to optimize rate-based light dose, and we present Dosie’s newly developed domination sub-maps method to improve the planning of the delivery of the effective rate-based light dose. We conclude that image-based treatment planning using Comsol or Dosie FEM-solvers is a valid approach to guide the light dosimetry in I-PDT of patients with MCAO.
Open AccessComputational Optimization of Irradiance and Fluence for Interstitial Photodynamic Therapy Treatment of Patients with Malignant Central Airway Obstruction
There are no effective treatments for patients with extrinsic malignant central airway obstruction (MCAO). In a recent clinical study, we demonstrated that interstitial photodynamic therapy (I-PDT) is a safe and potentially effective treatment for patients with extrinsic MCAO. In previous preclinical studies, we reported that a minimum light irradiance and fluence should be maintained within a significant volume of the target tumor to obtain an effective PDT response. In this paper, we present a computational approach to personalized treatment planning of light delivery in I-PDT that simultaneously optimizes the delivered irradiance and fluence using finite element method (FEM) solvers of either Comsol Multiphysics® or Dosie™ for light propagation. The FEM simulations were validated with light dosimetry measurements in a solid phantom with tissue-like optical properties. The agreement between the treatment plans generated by two FEMs was tested using typical imaging data from four patients with extrinsic MCAO treated with I-PDT. The concordance correlation coefficient (CCC) and its 95% confidence interval (95% CI) were used to test the agreement between the simulation results and measurements, and between the two FEMs treatment plans. Dosie with CCC = 0.994 (95% CI, 0.953–0.996) and Comsol with CCC = 0.999 (95% CI, 0.985–0.999) showed excellent agreement with light measurements in the phantom. The CCC analysis showed very good agreement between Comsol and Dosie treatment plans for irradiance (95% CI, CCC: 0.996–0.999) and fluence (95% CI, CCC: 0.916–0.987) in using patients’ data. In previous preclinical work, we demonstrated that effective I-PDT is associated with a computed light dose of ≥45 J/cm2 when the irradiance is ≥8.6 mW/cm2 (i.e., the effective rate-based light dose). In this paper, we show how to use Comsol and Dosie packages to optimize rate-based light dose, and we present Dosie’s newly developed domination sub-maps method to improve the planning of the delivery of the effective rate-based light dose. We conclude that image-based treatment planning using Comsol or Dosie FEM-solvers is a valid approach to guide the light dosimetry in I-PDT of patients with MCAO.
- Open Access
- 26 June 2022
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 3 (10) , 100372
First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies
- 26 June 2022
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 3 (10) , 100372
Open AccessFirst-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies
- 4 May 2022
- Published by Springer Nature
- Vol. 2451, 151-162
In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer
Interstitial photodynamic therapy (I-PDT) is a promising therapy considered for patients with locally advanced cancer. In I-PDT, laser fibers are inserted into the tumor for effective illumination and activation of the photosensitizer in a large tumor. The intratumoral light irradiance and fluence are critical parameters that affect the response to I-PDT. In vivo animal models are required to conduct light dose studies, to define optimal irradiance and fluence for I-PDT. Here we describe two animal models with locally advanced tumors that can be used to evaluate the response to I-PDT. One model is the C3H mouse bearing large subcutaneous SCCVII carcinoma (400–600 mm3). Using this murine model, multiple light regimens with one or two optical fibers with cylindrical diffuser ends (cylindrical diffuser fiber, CDF) can be used to study tumor response to I-PDT. However, tissue heating may occur when 630 nm therapeutic light is delivered through CDF at an intensity ≥60 mW/cm and energy ≥100 J/cm. These thermal effects can impact tumor response while treating locally advanced mice tumors. Magnetic resonance imaging and thermometry can be used to study these thermal effects. A larger animal model, New Zealand White rabbit with VX2 carcinoma (~5000 mm3) implanted in either the sternomastoid (neck implantation model) or the biceps femoris muscle (thigh implantation model), can be used to study I-PDT with image-based pretreatment planning using computed tomography. In the VX2 model, the light delivery can include the use of multiple laser fibers to test light dosimetry and delivery that are relevant for clinical use of I-PDT. Key words Interstitial photodynamic therapy Locally advanced cancer SCCVII VX2 carcinoma
- 4 May 2022
- Published by Springer Nature
- Vol. 2451, 151-162
In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer
Interstitial photodynamic therapy (I-PDT) is a promising therapy considered for patients with locally advanced cancer. In I-PDT, laser fibers are inserted into the tumor for effective illumination and activation of the photosensitizer in a large tumor. The intratumoral light irradiance and fluence are critical parameters that affect the response to I-PDT. In vivo animal models are required to conduct light dose studies, to define optimal irradiance and fluence for I-PDT. Here we describe two animal models with locally advanced tumors that can be used to evaluate the response to I-PDT. One model is the C3H mouse bearing large subcutaneous SCCVII carcinoma (400–600 mm3). Using this murine model, multiple light regimens with one or two optical fibers with cylindrical diffuser ends (cylindrical diffuser fiber, CDF) can be used to study tumor response to I-PDT. However, tissue heating may occur when 630 nm therapeutic light is delivered through CDF at an intensity ≥60 mW/cm and energy ≥100 J/cm. These thermal effects can impact tumor response while treating locally advanced mice tumors. Magnetic resonance imaging and thermometry can be used to study these thermal effects. A larger animal model, New Zealand White rabbit with VX2 carcinoma (~5000 mm3) implanted in either the sternomastoid (neck implantation model) or the biceps femoris muscle (thigh implantation model), can be used to study I-PDT with image-based pretreatment planning using computed tomography. In the VX2 model, the light delivery can include the use of multiple laser fibers to test light dosimetry and delivery that are relevant for clinical use of I-PDT. Key words Interstitial photodynamic therapy Locally advanced cancer SCCVII VX2 carcinoma
- Open Access
- 28 June 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (7) , 137
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. This TLD1433-mediated PDT induced an EC50 of 1.98 μM (J/cm2) and 4807 μM (J/cm2) for green and red light, respectively. Cells were then treated with 10 µM TLD1433 in a 96-well plate with the OSA using two 2-cm radial diffusers, each transmitted 532 nm light at 50 mW/cm for 278 s. Monte Carlo simulations of the surface light propagation from the OSA computed light fluence (J/cm2) and irradiance (mW/cm2) distribution. In regions where 100% loss in cell viability was measured, the simulations suggest that >20 J/cm2 of 532 nm was delivered. Our studies indicate that TLD1433-mediated PDT with the OSA and light simulations have the potential to become a platform for treatment planning for IO-PDT.
- 28 June 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (7) , 137
Open AccessTLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. This TLD1433-mediated PDT induced an EC50 of 1.98 μM (J/cm2) and 4807 μM (J/cm2) for green and red light, respectively. Cells were then treated with 10 µM TLD1433 in a 96-well plate with the OSA using two 2-cm radial diffusers, each transmitted 532 nm light at 50 mW/cm for 278 s. Monte Carlo simulations of the surface light propagation from the OSA computed light fluence (J/cm2) and irradiance (mW/cm2) distribution. In regions where 100% loss in cell viability was measured, the simulations suggest that >20 J/cm2 of 532 nm was delivered. Our studies indicate that TLD1433-mediated PDT with the OSA and light simulations have the potential to become a platform for treatment planning for IO-PDT.
- Open Access
- 30 December 2019
- Published by Wiley in Photochemistry and Photobiology
- Vol. 96 (2) , 397-404
Irradiance, Photofrin® Dose and Initial Tumor Volume are Key Predictors of Response to Interstitial Photodynamic Therapy of Locally Advanced Cancers in Translational Models
The objective of the present study was to develop a predictive model for Photofrin®‐mediated interstitial photodynamic therapy (I‐PDT) of locally advanced tumors. Our finite element method was used to simulate 630‐nm intratumoral irradiance and fluence for C3H mice and New Zealand White rabbits bearing large squamous cell carcinomas. Animals were treated with light only or I‐PDT using the same light settings. I‐PDT was administered with Photofrin® at 5.0 or 6.6 mg kg−1, 24 h drug‐light interval. The simulated threshold fluence was fixed at 45 J cm−2 while the simulated threshold irradiance varied, intratumorally. No cures were obtained in the mice treated with a threshold irradiance of 5.4 mW cm−2. However, 20–90% of the mice were cured when the threshold irradiances were ≥8.6 mW cm−2. In the rabbits treated with I‐PDT, 13 of the 14 VX2 tumors showed either local control or were cured when threshold irradiances were ≥15.3 mW cm−2 and fluence was 45 J cm−2. No tumor growth delay was observed in VX2 treated with light only (n = 3). In the mouse studies, there was a high probability (92.7%) of predicting cure when the initial tumor volume was below the median (493.9 mm3) and I‐PDT was administered with a threshold intratumoral irradiance ≥8.6 mW cm−2.
- 30 December 2019
- Published by Wiley in Photochemistry and Photobiology
- Vol. 96 (2) , 397-404
Open AccessIrradiance, Photofrin® Dose and Initial Tumor Volume are Key Predictors of Response to Interstitial Photodynamic Therapy of Locally Advanced Cancers in Translational Models
The objective of the present study was to develop a predictive model for Photofrin®‐mediated interstitial photodynamic therapy (I‐PDT) of locally advanced tumors. Our finite element method was used to simulate 630‐nm intratumoral irradiance and fluence for C3H mice and New Zealand White rabbits bearing large squamous cell carcinomas. Animals were treated with light only or I‐PDT using the same light settings. I‐PDT was administered with Photofrin® at 5.0 or 6.6 mg kg−1, 24 h drug‐light interval. The simulated threshold fluence was fixed at 45 J cm−2 while the simulated threshold irradiance varied, intratumorally. No cures were obtained in the mice treated with a threshold irradiance of 5.4 mW cm−2. However, 20–90% of the mice were cured when the threshold irradiances were ≥8.6 mW cm−2. In the rabbits treated with I‐PDT, 13 of the 14 VX2 tumors showed either local control or were cured when threshold irradiances were ≥15.3 mW cm−2 and fluence was 45 J cm−2. No tumor growth delay was observed in VX2 treated with light only (n = 3). In the mouse studies, there was a high probability (92.7%) of predicting cure when the initial tumor volume was below the median (493.9 mm3) and I‐PDT was administered with a threshold intratumoral irradiance ≥8.6 mW cm−2.
- 6 October 2019
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 52 (6) , 523-529
An Optical Surface Applicator for Intraoperative Photodynamic Therapy
Background and Objectives: Intraoperative photodynamic therapy (IO‐PDT) is typically administered by a handheld light source. This can result in uncontrolled distribution of light irradiance that impacts tissue and tumor response to photodynamic therapy. The objective of this work was to characterize a novel optical surface applicator (OSA) designed to administer controlled light irradiance in IO‐PDT.Study Design/Materials and Methods: An OSA was constructed from a flexible silicone mesh applicator with multiple cylindrically diffusing optical fibers (CDF) placed into channels of the silicone. Light irradiance distribution, at 665 nm, was evaluated on the OSA surface and after passage through solid tissue‐mimicking optical phantoms by measurements from a multi‐channel dosimetry system. As a proof of concept, the light administration of the OSA was tested in a pilot study by conducting a feasibility and performance test with 665‐nm laser light to activate 2‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) in the thoracic cavity of adult swine.Results: At the OSA surface, the irradiance distribution was non‐uniform, ranging from 128 to 346 mW/cm2. However, in the tissue‐mimicking phantoms, beam uniformity improved markedly, with irradiance ranges of 39–153, 33–87, and 12–28 mW/cm2 measured at phantom thicknesses of 3, 5, and 10 mm, respectively. The OSA safely delivered the prescribed light dose to the thoracic cavities of four swine.Conclusions: The OSA can provide predictable light irradiances for administering a well‐defined and potentially effective therapeutic light in IO‐PDT. Lasers Surg. Med.
- 6 October 2019
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 52 (6) , 523-529
An Optical Surface Applicator for Intraoperative Photodynamic Therapy
Background and Objectives: Intraoperative photodynamic therapy (IO‐PDT) is typically administered by a handheld light source. This can result in uncontrolled distribution of light irradiance that impacts tissue and tumor response to photodynamic therapy. The objective of this work was to characterize a novel optical surface applicator (OSA) designed to administer controlled light irradiance in IO‐PDT.Study Design/Materials and Methods: An OSA was constructed from a flexible silicone mesh applicator with multiple cylindrically diffusing optical fibers (CDF) placed into channels of the silicone. Light irradiance distribution, at 665 nm, was evaluated on the OSA surface and after passage through solid tissue‐mimicking optical phantoms by measurements from a multi‐channel dosimetry system. As a proof of concept, the light administration of the OSA was tested in a pilot study by conducting a feasibility and performance test with 665‐nm laser light to activate 2‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) in the thoracic cavity of adult swine.Results: At the OSA surface, the irradiance distribution was non‐uniform, ranging from 128 to 346 mW/cm2. However, in the tissue‐mimicking phantoms, beam uniformity improved markedly, with irradiance ranges of 39–153, 33–87, and 12–28 mW/cm2 measured at phantom thicknesses of 3, 5, and 10 mm, respectively. The OSA safely delivered the prescribed light dose to the thoracic cavities of four swine.Conclusions: The OSA can provide predictable light irradiances for administering a well‐defined and potentially effective therapeutic light in IO‐PDT. Lasers Surg. Med.